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CRISPR-mediated rapid generation of neural
cell-specific knockout mice facilitates
research in neurophysiology and pathology
Dan Xiao,1,4 Weifeng Zhang,1,2,4 Qing Wang,1 Xing Li,2 Yuan Zhang,2 Javad Rasouli,1 Giacomo Casella,1
Bogoljub Ciric,1 Mark Curtis,3 Abdolmohamad Rostami,1 and Guang-Xian Zhang1
1Department of Neurology, Thomas Jefferson University, Philadelphia, PA 19107, USA; 2College of Life Sciences, Shaanxi Normal University, Xi’an, Shaanxi 710062, China;
3Department of Pathology, Thomas Jefferson University, Philadelphia, PA 19107, USA
Inducible conditional knockout mice are important tools for
studying gene function and disease therapy, but their genera-
tion is costly and time-consuming. We introduced clustered
regularly interspaced short palindromic repeats (CRISPR)
and Cre into an LSL-Cas9 transgene-carrying mouse line by us-
ing adeno-associated virus (AAV)-PHP.eB to rapidly knockout
gene(s) specifically in central nervous system (CNS) cells of
adult mice. NeuN in neurons and GFAP in astrocytes were
knocked out 2 weeks after an intravenous injection of vector,
with an efficiency comparable to that of inducible Cre-loxP
conditional knockout. For functional testing, we generated
astrocyte-specific Act1 knockout mice, which exhibited a
phenotype similar to mice with Cre-loxP-mediated Act1
knockout, in an animal model of multiple sclerosis (MS), an
autoimmune disorder of the CNS. With this novel technique,
neural cell-specific knockout can be induced rapidly (few
weeks) and cost-effectively. Our study provides a new approach
to building inducible conditional knockout mice, which would
greatly facilitate research on CNS biology and disease.
INTRODUCTION
Development of inducible conditional gene knockout mouse lines
through breeding of CreER-donor and loxP-carrying mice, with typi-
cally 70%–80% knockout efficiency of a target gene, allows for time-
controlled and cell-specific gene modification.1,2While this technique
is a cornerstone in basic scientific studies on disease mechanisms and
pre-clinical studies of potential therapies, it is time- and labor-
consuming to generate CreER and loxP mice, to obtain certain spe-
cific mouse lines from non-commercial resources, and then to breed
and genotype them to generate homozygous CreER-loxP mice. The
clustered regularly interspaced short palindromic repeats
(CRISPR)-CRISPR-associated (Cas)-based genome-editing tech-
nique has a proven capacity for efficient genome editing.3–7
CRISPR-mediated gene knockout in vivo has the advantage of being
time-, labor-, and cost-saving compared with the Cre-loxP breeding
method. Highly efficient CRISPR-mediated gene knockout has been
achieved to develop disease models in peripheral tissues such as
lung and liver.5,7–11 However, efficient gene knockout in the central
nervous system (CNS) using CRISPR is limited by the blood-brain
barrier (BBB). Some attempts have been made to edit genes by stereo-
taxic intracerebral injections into the CNS of adult mice,12–14 or to
take advantage of the underdeveloped BBB of neonatal mice to
knockout genes in neurons.15 However, we still do not have a method
to knock out genes of a specific cell type in the entire adult CNS. The
development of adeno-associated virus (AAV)-PHP.eB, a new variant
of AAV9 that can transduce neurons, astrocytes, and oligodendro-
cytes, but not microglia, with high efficiency through intravenous
(i.v.) injection,16 makes this possible.
In the present study, we combined an AAV-PHP.eB, CRISPR, and
LSL-Cas9 mouse line to build a method that knocks out genes rapidly,
efficiently, and cell specifically in the entire CNS. We knocked out
NeuN specifically in neurons and GFAP specifically in astrocytes
with an efficiency comparable with that of the CreER-loxP method.
Finally, we generated astrocyte-specific Act1 knockout mice, which
showed a phenotype similar to mice generated using the Cre-loxP
method when tested in experimental autoimmune encephalomyelitis
(EAE), a mouse model for MS. Our data demonstrate that our
approach is a powerful method for neurophysiological and patholog-
ical research.
RESULTS
Neuron-specific knockout of NeuN using AAV PHP.eB-CRISPR
Owing to the size limitationsofAAVvectors,17 there is not enough space
for Cas9, single guide RNA (sgRNA), and a tissue-specific promoter to
be included in the same vector.We thus generated theAAVPHP.eBvec-
tor carrying sgRNAandCre gene that is expressed under the control of a
neural cell-specific promoter (Figure 1A). This vector was i.v. injected
into LSL-Cas9 transgenic mice on a C57BL/6 background, carrying a
Cas9-P2A-GFP cassette driven by the inactive CAG promoter due to
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a floxed stop signal18 (Figure 1B). In this manner, CNS-specific
knockout mice can be generated in less than 1 month, which is much
more rapid and easier than the traditional Cre-loxP-based conditional
gene knockout method (Figure 1C; Table S1). Cell-specific gene
knockout was first tested using a neuron-specific promoter, hSYN1, to
knock out NeuN, a neuron marker. Three target sites for sgRNAs
were selected (Figure 1D), sgRNA carrying plasmids were transfected
into the N2A-C9 cell line, and sgRNA activity was analyzed by a T7
endonuclease 1 (T7E1) assay (Figure 1E). To avoid sense mutation
induced by single sgRNA, two sgRNAs (#1 and #2) with the highest ac-
tivity were cloned in series into the AAV transfer plasmid to further
improve knockout efficiency; the plasmid was named pAAV-sgNeuN-
hSYN1-Cre. Cleaving efficiency of plasmid carrying two sgRNAs was
also analyzed in the N2A-C9 cell line (Figure 1F). The corresponding
AAVs were produced and purified as reported,16 and named PHP.eB-
sgNeuN-hSYN1-Cre. Control plasmid named pAAV-sgRNA scramble
(sgScram)-hSYN1-Cre was generated by replacingNeuN sgRNAwith a
scramble sgRNA, and the resulting virus was named PHP.eB-sgScram-
hSYN1-Cre.ToknockoutNeuN invivo, 5 1011 vector genomes (vg) of
AAV were injected per mouse through the tail vein, with three mice in
each group. The knockout efficiency was analyzed by immunostaining
and flow cytometry 2 weeks after injection (Figure 2). In the spinal
cord of PHP.eB-sgScram-hSYN1-Cre-injected mice, about 72% of
NeuN+ cells were GFP+, which indicates Cas9 expression in neurons,
while only 2% of NeuN cells expressed GFP (Figure 2A). This demon-
strates highly efficient and specific gene expression in the target cells. In-
jectionofPHP.eB-sgNeuN-hSYN1-Cre knockedoutNeuN in65%of to-
tal neurons (from 9.35% down to 3.32%; Figure 2A). This result was
confirmed by immunostaining showing a 66% reduction inNeuN+ cells
(from 26.05% down to 8.83%) (Figures 2B and 2C).NeuNwas knocked
out in 98%ofGFP+ neurons, i.e., from93% in the control groupdown to
2% in the NeuN sgRNA-carrying AAV group (Figure 2D). NeuN
knockout in the cerebrum was also analyzed, as exemplified by immu-
nofluorescence images of the cortex (Figures 3A and 3B), hippocampus
Figure 1. Schematic illustration of AAV-CRISPR-mediated CNS-specific knockout and NeuN targeting sgRNA selection in vitro
(A) Diagram of the structure of AAV transfer plasmid used. TSP, tissue-specific promoter. (B) Diagram of the structure of transgene in LSL-Cas9 mice. (C) Cartoon shows the
timeline of the Cre-loxP or CRISPR-based conditional gene knockout method. (D) Location of sgRNAs targetingNeuN and detection primers on the genome. (E) T7E1 assay
of single NeuN sgRNA activity. (F) T7E1 assay of the cleavage efficiency of two NeuN sgRNAs.
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(Figure 3C), and thalamus (Figure S1). Statistical analysis of the immu-
nofluorescence data showed thatNeuNwas knocked out in 82.2%of the
total NeuN+ cells (from 38.96% down to 6.94%; Figure 3D) and in 99%
of transduced (GFP+) neurons (Figure 3E) after treatment with NeuN-
sgRNA-carryingAAV. It has been reported that the liver and heart were
heavily transduced by AAV PHP.eB in rats.19 We thus tested whether
Figure 2. Neuron-specific NeuN knockout in spinal cord
PHP.eB-sgNeuN-hSYN1-Cre or PHP.eB-sgScram-hSYN1-Cre was i.v. injected into naive adult LSL-Cas9 mice, 8–10 weeks of age, at 5 1011 vg per mouse. Spinal cords
were harvested 2 weeks later for flow cytometry analysis or immunostaining. (A) Flow cytometry analysis of NeuN+ cells in the spinal cord of PHP.eB-sgNeuN-hSYN1-Cre
versus control groups, and GFP+ cells in the NeuN+ cells and NeuN cells. One representative result of two independent experiments is shown. (B) Representative confocal
images of GFP and NEUN staining in the transverse spinal cord sections. Scale bars, 50 mm. (C and D) Data shown in (B) were quantified for the knockout efficiency in total
neurons (C) or vector-transduced (GFP+) neurons (D). Data in (C) and (D) are shown asmean ± SD (n = 3mice per group, five to six images for eachmouse). ****p < 0.0001, by
an unpaired two-tailed t test.
www.moleculartherapy.org
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our virus induced GFP expression in liver and heart, which may lead to
undesirable expression ofCas9 in the peripheral tissue. Immunostaining
of these organs from AAV-Scram sgRNA-transduced LSL-Cas9 mice
showed no GFP+ cells (Figure S2), indicating that our neuron-specific
targeting AAV virus is not active in peripheral tissues, most likely
because of the high specificity of the hSYN1 (neuron-specific) promoter.
Astrocyte-specific knockout of GFAP using AAV PHP.eB-
CRISPR
To test the efficiency of gene knockout in astrocytes, we replaced the
hSYN1 promoter by a GFAP promoter. The GFAP gene, a marker for
astrocytes, was chosen as the target gene to knock out. Four sgRNAs
targeting the GFAP gene were selected (Figure 4A), and sgRNA activ-
ities were tested in the N2A-C9 cell line and analyzed by a T7E1 assay
(Figure 4B). Two sgRNAs with the highest efficiency (#3 and #4) were
selected and cloned successively into an AAV-transfer plasmid that
carries the GFAP promoter and Cre gene, and cleavage efficiency
was analyzed in the N2A-C9 cell line (Figure 4C). AAV was i.v. in-
jected into adult mice as described in Figure 2, with three mice in
each group. The transduction efficiency and specificity in CNS cells
were analyzed 2 weeks later by flow cytometry. In mice injected
with PHP.eB-sgScram-GFAP-Cre, up to 86% of astrocytes in the spi-
nal cord (Figure 4D) and 54% in the cerebrum (Figure 4E) were trans-
duced by AAV, as indicated by GFP expression. The transduction
specificity in the spinal cord was high, since only 6.8% of GFAP cells
expressed GFP (Figure 4D), whereas transduction specificity in the
cerebrum (Figure 4E) was lower than in the spinal cord. Knockout ef-
ficiencies were also analyzed by western blot. Injection of GFAP-tar-
geting AAV reduced GFAP expression by 79% in spinal cord and 46%
in cerebrum (Figures 4F and 4G). These results show that CRISPR-
carrying AAV knocked out the GFAP gene in astrocytes of the spinal
cord with high efficiency and specificity, but the knockout efficiency
Figure 3. Neuron-specific NeuN knockout in cerebrum
Brains from PHP.eB-sgNeuN-hSYN1-Cre- or PHP.eB-sgScram-hSYN1-Cre-injected mice were harvested 2 weeks after injection and analyzed by immunostaining. (A–C)
Representative confocal images of GFP and NEUN staining in the cortex (A and B) and hippocampus (C). Arrows in (B) depict GFP and NEUN double-positive cells in the
PHP.eB-sgNeuN-hSYN1-Cre-injected group. For (A) and (B): scale bars, 100 mm, scale bars of zoomed images, 20 mm; for (C), scale bars, 50 mm. (D and E) Quantification of
knockout efficiency in total neurons (D) or vector-infected transduced (GFP+) neurons (E) in the cerebrum. Data in (D) and (E) are shown as mean ± SD (n = 3 mice per group,
five to six images for each mouse). ****p < 0.0001, by an unpaired two-tailed t test.
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and specificity in the cerebrum were somewhat low. This could be
because the GFAP promoter activity in some cerebrum astrocytes is
not high enough to induce the expression of Cre.20 Nonetheless,
our method shows efficiency comparable with reports that GFAP-
Cre/loxP conditional knockout mice have a 70%–80% knockout
efficiency.21,22
Functional test in vivo
For in vivo functional assessment, we compared the conditional
knockout mice generated using our method with Cre-loxP mice.
Act1 is an essential intracellular adaptor for interleukin (IL)-17A
signaling, which is important for the development of EAE.23,24 Signif-
icantly reduced EAE severitywas seen inmicewithCre-loxP-mediated
knockout of Act1 in neuroectoderm-derived cells, in which astrocytes
are a major part, in addition to neurons and oligodendrocytes.25 To
knock out Act1 in astrocytes in adult mice, four sgRNAs targeting
mouse Act1 were designed and screened (Figures 5A and 5B). Two
sgRNAs with the highest efficiency (# 2 and #3) were successively
cloned into GFAP-Cre-carrying AAV transfer plasmid, and activity
was tested in vitro (Figure 5C). Mice were injected through the tail
vein with Act1-targeting AAV (five mice) and control AAV (seven
mice). Ten days later, mice were immunized for EAE induction and
were sacrificed 30 days post-immunization (p.i.), after which trans-
duction efficiency in the spinal cord, where the main EAE lesions
are located, was analyzed by immunostaining. Astrocytes in both
white and gray matter were transduced by AAV with high efficiency,
as shown by a large number of GFP+GFAP+ cells (Figure 6A and 6B),
likely owing to the activation of astrocytes during EAE. This was in
contrast to naive mice, in which mainly astrocytes in white matter
were transduced (as shown in Figure S3). Act1 in astrocytes was
knocked out with high efficiency, as shown by immunostaining (Fig-
ures 6C and 6D). Mice injected with AAV that targets Act1 had
Figure 4. Astrocyte-specific GFAP knockout in vivo
(A) Location of sgRNAs targetingGFAP and detection primers on the genome. (B) T7E1 assay of single GFAP sgRNA activity. (C) T7E1 assay of the cleavage efficiency of two
GFAP sgRNAs. PHP.eB-sgGFAP-GFAP-Cre or PHP.eB-sgScram-GFAP-Cre was i.v. injected into naive adult LSL-Cas9mice, 8–10weeks of age, at 5 1011 vg per mouse.
(D and E) GFAP expression in spinal cord (D) and cerebrum (E) of mice that received PHP.eB-sgScram-GFAP-Cre was determined at 2 weeks after injection by flow cy-
tometry. n = 2 mice each group. (F) Western blot analysis of the knockout efficiency ofGFAP in spinal cord (top panel) and cerebrum (bottom panel). AAV-injected mice were
sacrificed 2 weeks after injection and astrocytes were purified using an ACSA-2 MicroBead kit. The isolated astrocytes were lysed by RIPA buffer andGFAP expression was
determined by western blot. (G) Quantification ofGFAP knockout efficiency was determined by the density of the western blot bands. The results are presented as the ratio of
density between GFAP and GAPDH. The density of bands was analyzed using ImageJ. Data are shown as mean ± SD (n = 3mice per group). **p < 0.01, ****p < 0.0001, by a
one-way ANOVA.
www.moleculartherapy.org
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delayed and ameliorated EAE development compared to control mice
(Figure 6E), with significantly reduced numbers of CNS-infiltrating
mononuclear cells (Figure 6F). The size and number of GFAP+ cells
in the Act1 knockout group were also greatly reduced, most likely
owing to reduced astrocyte activation (Figure 6C). These results
show that CRISPR-mediated conditional knockout mice have similar
characteristics as Cre-loxP conditional knockout mice, thus validating
the usefulness of this approach in studies that involve the CNS. AAV
can also be injected at the onset or peak of disease for therapeutic
studies.
DISCUSSION
Our present study provides a novel technique to generate inducible
conditional knockout animals, with several significant advantages
over currently used approaches. (1) The current technique to generate
inducible, conditional gene knockout mouse lines is cost- and time-
consuming, requiring months or even years to establish, while our
approach requires a few weeks in vitro, and 1–2 weeks in vivo to knock
out the gene(s) of interest in a specific CNS cell type. (2) The mouse
lines (e.g., flox/flox and Cre-ER) necessary to generate inducible con-
ditional knockout of a particular gene in a specific cell type are often
unavailable, precluding relevant in vivo experiments, while any
gene(s) of interest can be readily knocked out using our technique.
(3) Compared with intra-CNS injections that typically knock out
genes only in an area proximal to the injection site, i.v. injection of
PHP.eB serotype AAV, an ideal tool for CNS delivery,16 knocks out
genes throughout the CNS. Also, i.v. injection is easy to perform
and causes less stress to the mice, which is important in some disease
models affected by stress, e.g., EAE.26,27 (4) To save enough space for a
tissue-specific promoter in AAV transfer plasmid and to further
improve knockout efficiency, we used an LSL-Cas9 transgene mouse
line with a C57 background, available from The Jackson Laboratory
and suitable for most disease models. The GFP reporter gene in the
transgene of LSL-Cas9 mice is a convenient marker for identification
of knockout cells. (5) Replacement of Cas9 from Streptococcus pyo-
genes (spCas9) with Staphylococcus aureus Cas9 (saCas9) could allow
cloning of a tissue-specific promoter, Cas9 and sgRNA, in a single
plasmid, given that saCas9 is smaller than spCas9. This would extend
the applicability of our method to more animal types and back-
grounds. (6) Our approach can also be used to knock out multiple
genes simultaneously in multiple CNS cell types with a combination
of different viruses.
In summary, we have established a rapid, simple, and economic
approach to cell-specific gene knockout in CNS cells, whereby any
gene(s) of interest can be knocked out in a short time (about 2 weeks).
This technique has the capacity to significantly simplify the inducible
conditional knockout mouse system for CNS studies in vivo.
MATERIALS AND METHODS
Cell culture
The N2A-Cas9 cell line was purchased from Genecopoeia (Rockville,
MD, USA) and grown in DMEM containing 10% fetal bovine serum
(FBS). HEK293T cells were also grown in DMEM containing 10%
FBS. Cells were maintained at 37C in 5% CO2 atmosphere.
Mice
LSL-Cas9 (stock no. 026175) mice were obtained from The Jackson
Laboratory (Bar Harbor, ME, USA). Mice, 8–10 weeks old, with a
body weight of approximately 20 g were used in all experiments in
this study. Mice were kept in a specific pathogen-free animal facility
at Thomas Jefferson University. All experiments were carried out in
accordance with guidelines by the Institutional Animal Care and
Use Committee (IACUC) of Thomas Jefferson University.
Plasmid
lentiCRISPRv2 (Addgene plasmid #52961) andAAV:inverted terminal
repeat (ITR)-U6-sgRNA (backbone)-pCBh-Cre-WPRE-hGHpA-ITR
(Addgene plasmid #60229) were provided by Dr. Feng Zhang.
pAAV-hSyn1-mRuby2 was provided by Viviana Gradinaru (Addgene
plasmid #99126). lentiCRISPR v2 was used as a template to amplify
U6, using U6 KpnI forward and U6 SfuI reverse primers. The acquired
fragment was used to replace the U6 promoter in lentiCRISPR v2
throughKpnIandSfuI to introduce anXbaI beforeU6, and the obtained
plasmid was named lentiCRISPR v3 (Figure S4). sgRNAs targeting
NeuN, GFAP, and Act1 were designed using https://www.benchling.
com/crispr/; corresponding primers were synthesized by Integrated
DNA Technologies (IDT, Coralville, IA, USA). Primers were annealed
and ligated into lentiCRISPR v3 through BsmBI to test cleaving effi-
ciency in the N2A-C9 cell. To clone two sgRNAs in one plasmid, the
U6-sgRNA fragment was cleaved from the first plasmid through
KpnI and NheI and inserted into the second plasmid through KpnI
and XbaI. Scramble sgRNA was also cloned into lentiCRISPR v3 as
control.
Primers for the MPAA linker were synthesized and annealed at room
temperature. TheMPAA linker was cloned into AAV:ITR-U6-sgRNA
Figure 5. Act1 sgRNA design and activity assay
(A) Location of sgRNAs targeting Act1 and detection primers on the genome. (B)
T7E1 assay of single Act1 sgRNA activity. (C) T7E1 assay of the cleavage efficiency
of two Act1 sgRNAs.
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(backbone)-pCBh-Cre-WPRE-hGHpA-ITR to replace U6-sgRNA-
pCBH cassette through MluI and AgeI; the resulting plasmid was
named pAAV-MCS-Cre. For neuron-specific gene knockout, the
hSYN1 promoter was amplified from pAAV-hSyn1-mRuby2 and
cloned into pAAV-MCS-Cre through NheI and AscI; the resulting
plasmid was named pAAV-MCS-hSYN1-Cre (Figure S5A). U6-
sgRNA expression cassettes carrying two NeuN sgRNAs or scrambled
sgRNAs were cleaved from lentiCRISPR v3 and cloned into pAAV-
MCS-hSYN1-Cre separately through KpnI and NheI; the resulting
plasmid was named pAAV-sgNeuN-hSYN1-Cre or pAAV-sgScram-
hSYN1-Cre.
For astrocyte-specific gene knockout, the GFAP promoter was ampli-
fied from the pLenti-Gfap-eGFP-mir30-shAct1 vector28 and cloned
into pAAV-MCS-Cre through NheI and AscI; the resulting plasmid
was named pAAV-MCS-GFAP-Cre (Figure S5B). For U6-sgRNA
expression cassettes carrying two GFAP sgRNAs, two Act1 sgRNAs
or scrambled sgRNAs were cleaved from lentiCRISPR v3 and ligated
Figure 6. Astrocyte-specific Act1 knockout in vivo and EAE induction
PHP.eB-sgAct1-GFAP-Cre or control virus was i.v. injected into naive adult LSL-Cas9 mice, 8–10 weeks old, at 5  1011 vg per mouse 10 days before immunization. Mice
were sacrificed at day 30 p.i. and transduction/knockout efficiencies were analyzed by immunostaining. (A) Representative confocal image of GFP and GFAP staining in the
transverse spinal cord sections. Scale bar, 50 mm. (B) Representative confocal image of GFP and GFAP staining in the white matter of spinal cord with a prolonged GFP
exposure time. Scale bar, 100 mm; scale bar of zoomed images, 20 mm. (C) Immunostaining analysis of Act1 knockout in the spinal cord of EAE mice. Scale bar, 100 mm;
zoomed images show representative cells, scale bar, 20 mm. (D) Quantification of Act1 expression in astrocytes, as calculated by the intensity of GFAP+Act1+ cells divided by
the intensity of GFAP+ cells in the spinal cord. (E) EAE scores. (F) Statistical analysis of numbers of immune cells infiltrated into the CNS. Mononuclear cells from the CNS of
mice in (E) were isolated by Percoll gradient centrifugation and counted using a cell counter. All data are shown as mean ± SD (n = 7 for scramble sgRNA, n = 5 for Act1
sgRNA). ***p < 0.001, ****p < 0.0001, by an unpaired two-tailed t test. One representative of two independent experiments is shown.
www.moleculartherapy.org
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into pAAV-MCS-GFAP-Cre separately, through KpnI and NheI; the
resulting plasmid was named pAAV-sgGFAP-GFAP-Cre, pAAV-
sgAct1-GFAP-Cre, or pAAV-sgScram-GFAP-Cre.
All of the primers used are listed in Table S2.
pAdDeltaF6 was provided by James M. Wilson (Addgene plasmid
#112867); pUCmini-iCAP-PHP.eB was provided by Viviana Gradi-
naru16 (Addgene plasmid #103005).
AAV packaging and purification
The AAV particles were generated as reported by Chan et al.16 Briefly,
low-passaged 293T cells were transfected with transfer plasmid, pUC-
mini-iCAP-PHP.eB and pAdDeltaF6 using PEI-MAX (Polysciences,
Warrington, PA, USA). Viral particles were collected at 72 h after
transfection from the medium, and at 120 h after transfection from
the cells and medium. The viruses were then purified by iodixanol
(Sigma, St. Louis, MO, USA) step gradients (15%, 25%, 40%, and
60%),29 concentrated using Amicon filters (EMD Millipore, Burling-
ton, MA, USA), and formulated in sterile PBS with 0.001% Pluronic
F-68 (Gibco, Gaithersburg, MD, USA). Virus titers were measured by
determining the number of DNase I-resistant vg using qPCR, with a
linearized genome plasmid as the standard.30
Isolation of cells from adult mouse CNS
Mice were perfused with 1 PBS and the isolated brain or spinal cord
was chopped with a razor blade. Tissues were digested into single-cell
suspensions, and myelin was removed using an adult brain dissocia-
tion kit (Miltenyi Biotec, Gaithersburg, MD, USA). Cells were re-sus-
pended in PBS for flow cytometry analysis or specific cell isolation.
For western blot, astrocytes were isolated from single-cell suspension
using an anti-ACSA-2 MicroBead kit (Miltenyi Biotec) following the
manufacturer’s instructions. The purified astrocytes were re-sus-
pended in PBS for western blot analysis.
Immunofluorescent labeling and imaging
Frozen tissues were cut into 10-mm sections. Frozen sections were air-
dried, rehydrated in Tris-buffered saline (TBS), permeabilized by TBS
with 0.2%TritonX-100, and blocked inTBSwith 10%horse serumand
1% BSA for 30 min. The primary antibodies were then incubated in
TBS with 1% BSA at 4C overnight. The following day, the slides
were washed three times in TBS with 0.025% Triton X-100 and incu-
bated with secondary antibody (Jackson ImmunoResearch, West
Grove, PA,USA) inTBSwith 1%BSAat room temperature for 1 h.An-
tibodies used were as follows: anti-NeuN clone A60 (EMDMillipore),
anti-GFP (Abcam, Branford, CT,USA), anti-GFAP cloneD1F4Q (Cell
Signaling Technology [CST], Danvers,MA,USA), and anti-Act1 clone
WW-18 (Santa Cruz Biotechnology, Dallas, TX, USA).
Finally, all of the sections were washed and mounted in Prolong Gold
antifade reagent with DAPI (Invitrogen, Carlsbad, CA, USA). Imaging
was performedusing aNikonA1Rmicroscope andNikonNISElements
acquisition and analysis software. Images were processed and analyzed
by ImageJ.
Flow cytometry
Cells were first stained with surface antibodies at 4C for 20 min, fixed
by medium A (Invitrogen), washed, and then incubated with intracel-
lular antibodies inmediumB (Invitrogen) at 4Covernight. Antibodies
used in these experiments were as follows: anti-NeuN-phycoerythrin
(PE) clone A60 (EMD Millipore), anti-GFP-AF488 (Invitrogen), and
anti-GFAP-AF647 clone 2.2B10 (Invitrogen). Compensation was per-
formed using UltraComp eBeads (Invitrogen).
Western blot
1  106 astrocytes were lysed in 100 mL of radioimmunoprecipitation
assay (RIPA) lysis buffer (ThermoScientific,Waltham,MA,USA) con-
taining protease inhibitors (Sigma). Cells were incubated on ice for
30 min and sonicated on ice for 20 s. Cell lysate was centrifuged at
10,000 rpm for 10 min at 4C and supernatant was collected. Protein
concentration in the supernatant was determined using the bicinchro-
ninic acid (BCA) protein assay kit (Pierce Biotechnology, Waltham,
MA, USA). Protein lysate was diluted in SDS-PAGE sample buffer,
separated on Novex 4%–12% Tris-glycine gel (Invitrogen), and
analyzed bywestern blot using rabbit anti-GFAPmonoclonal antibody
(CST). GAPDH was stained with rabbit anti-GAPDH monoclonal
antibody (CST) and used as loading control.
T7E1 assay
N2A-C9 cells were seeded in a 24-well plate at 1  105 cells per well
and, on the following day, were transfected with a mixture containing
0.5 mg of plasmid and 1 mL of Lipofectamine 2000. Medium was
changed on the next day, and cells were collected 48 h after transfec-
tion. Genomic DNA was extracted using QuickExtract DNA extrac-
tion solution (Lucigen, Middleton, WI, USA). PCR reactions were
performed using PrimeSTAR HS DNA polymerase (Takara, Moun-
tain View, CA, USA), using the respective PCR primers. The PCR
products were subjected to denaturation and reannealing using a
thermocycler and purified using a Monarch PCR & DNA cleanup
kit (NEB, Ipswich, MA, USA). The cycle conditions used for denatur-
ation and reannealing were 95C for 2 min, ramp at 2C/s until 85C
was reached followed by 85C for 2 min, ramp at 0.1C/s until 25C,
25C for 2 min, and then kept at 16C until used for T7E1 digestion.
Purified PCR products (300 ng) were digested by 0.5 mL of T7E1 at
37C for 20 min. The resulting products were separated on 2%
agarose gel and imaged by Axygen gel documentation systems.
EAE induction
LSL-Cas9mice, 8–10 weeks of age, were used for EAE induction. Mice
were immunized subcutaneously at two sites on the back with 200 mg
of myelin oligodendrocyte glycoprotein (MOG)35–55 peptide (Gen-
Script, Piscataway, NJ, USA) emulsified in complete Freund’s adju-
vant (BD Biosciences, San Jose, CA, USA) supplemented with
10 mg/mL Mycobacterium tuberculosis H37Ra (BD Biosciences).
Mice were also injected intraperitoneally with 200 ng of pertussis
toxin (Sigma, St. Louis, MO, USA) on days 0 and 2 p.i. Mice were
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monitored for weight changes and clinical signs until 30 days p.i.
Clinical signs were scored by two separate researchers in a blinded
manner using a 0–5 scale: 0, no clinical sign; 1, limp tail; 2, limp
tail with weak/partially paralyzed hind legs; 3, limp tail with complete
paralyzed hind legs; 4, tetraplegia; 5, moribund.
Statistical analysis
Statistical analyses were performed with Prism software (GraphPad).
An unpaired two-tailed t test was used for comparison of two groups.
Two-way ANOVA was used for comparison of more than two
groups. p values of <0.05 were considered significant. All error bars
represent SD, as noted in the individual figure legends.
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